IONIS Pharma (Nasdaq: IONS) Portfolio, Stock and Financial Highlights

Ionis Pharmaceuticals Highlights 

- Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics
- Three approved commercial RNA targeted therapies: SPINRAZA, TEGSEDI, WAYLIVRA
- Numerous in house and out liscened collaborative program
- Net income of $5 million on a non-GAAP basis 
- Cash equivalents, and short-term investments of more than $2.3 billion,
 

Pages You May Like